I know everyone is focused on today's upgrades in spite of LA & NY hoping on the investigation. Does anyone have any comments on the company's plans to:
1) "reenergize the "Synacthen business"
2) "globalize both Synacthen and Acthar"
3) "grow shareholder value through acquisitions or partnering on other promising drugs"
4) Don's statement in the Q&A about interest in M&A and diversifying
5) Anything else from the conference call